Home > Insider Trading > Filing (0001415889-13-001643)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070494	Acadia Pharmaceuticals Inc	ACAD	Pharmaceutical Preparations (2834)	061376651

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1291969	H Thomas Aasen	3911 Sorrento Valley Blvd San Diego CA 92121	Exec Vp, Cfo And Cbo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-08-13	30,000	$1.55	76,585	No	4	M	Direct
Common Stock	Acquisiton	2013-08-13	15,000	$1.55	91,585	No	4	M	Direct
Common Stock	Disposition	2013-08-13	60,000	$0.00	31,585	No	5	G	Direct
Common Stock	Acquisiton	2013-08-13	60,000	$0.00	60,000	No	5	G	Indirect	By Family Trust
Common Stock	Disposition	2013-08-13	60,000	$20.15	0	No	4	S	Indirect	By Family Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	M	Direct
No	5	G	Direct
No	5	G	Indirect	By Family Trust
No	4	S	Indirect	By Family Trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2013-08-13	30,000	$0.00	30,000	$1.55
Common Stock	Stock Option (right to buy)	Disposition	2013-08-13	15,000	$0.00	15,000	$1.55

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
82,263	2011-03-12	2020-03-11	No	4	M	Direct
58,708	2011-03-12	2020-03-11	No	4	M	Direct

Footnotes

Includes 2,085 shares acquired on May 31, 2013 by Mr. Aasen under the ACADIA Pharmaceuticals Employee Stock Purchase Plan.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2012.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.80 to $20.43 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.